Retro Biosciences drugs aging itself — Sam Altman's $180M seed reaches first human trial

A San Francisco biotech developing drugs against the biology of aging: RTR242 restores lysosomal function, reprogramming therapies rewind cells, microglia cell therapies reset brain immune cells.

Treat aging's own biology — autophagy, cellular reprogramming, microglia — as the disease and prove it in randomized human trials.

$180M seed (sole investor Sam Altman, 2023); $1B Series A announced Jan 2025

Founded in 2022 in San Francisco by Joe Betts-LaCroix, a longevity-scene veteran (Halcyon Molecular, Foresight Institute) whose stated goal is adding 10 years of healthy life. Sam Altman supplied the entire $180M seed round in 2023 — at the time his largest known personal investment.

January 2025: FT and TechCrunch reported Retro was raising a $1B Series A, with Altman joining. The same month it published its OpenAI collaboration — a protein-engineering model that redesigned the reprogramming factors tested in its labs. December 2025: first participant dosed in a Phase 1 trial of RTR242, its autophagy-restoring small molecule, in Adelaide, Australia.

Clinical-stage since 2025. No efficacy data yet: the Phase 1 study measures safety and autophagy biomarkers; Alzheimer's is the first indication Retro will chase if the biology shows signal.

It chose regulatory credibility over narrative: trial design, blinding, healthy volunteers — milestones a skeptic can check — instead of mouse-lab claims.

It stacked capital early ($180M, then a $1B raise) so the biology would not starve before first data.

It used AI as an instrument, not a slogan: the OpenAI-built proteins moved a concrete lab assay, keeping the story verifiable.

It kept three independent programs, so one molecule's failure does not sink the company.

A moonshot pitch scales when you convert it into checkable milestones — trials, biomarkers, filings. Those turn a celebrity check into a company others can verify and bet on.

As of September 2026 Retro is a clinical-stage company with three programs and no marketed product. Its Phase 1 reads out safety and mechanistic biomarkers rather than lifespan gains, and reported plans include expanding early trials toward Alzheimer's and Parkinson's indications. The real test — whether cellular aging can be measurably slowed in people — will take years of trials. Its market position depends less on science headlines than on the unusual capital runway Altman's checks and a six-figure-plus Series A provided.